Loyal's Vet-driven B2B2C Model

This model makes veterinarian trust the real go to market bottleneck, not consumer awareness. Loyal can market the idea of longer healthy lives for dogs, but the sale happens only when a vet is willing to prescribe, explain dosing, monitor the animal, and handle refills or in clinic injections. That looks much more like heartworm, arthritis, and other chronic pet medications than a typical consumer wellness subscription.

• Loyal is building around products that fit existing clinic workflows. LOY-002 is a daily prescription pill, while LOY-001 is a long acting injection given in clinic. That matters because vets already make money and manage care through these same prescribing and administration patterns.
  1 sacra 2 loyal 3 loyal
• The B2B2C setup also widens distribution beyond a single clinic visit. Chewy Pharmacy fills pet prescriptions only with veterinarian authorization, and offers autoship style refills. That creates a path where the vet initiates the therapy and an online pharmacy can support recurring fulfillment over time.
  5 chewy 6 chewy 7 chewy
• Regulation reinforces the channel. FDA guidance says conditionally approved animal drugs can reach market once they are shown safe and reasonably likely to work, but they remain veterinary drugs. For some newer dog treatments, FDA explicitly requires prescription use because dosing, administration, and adverse event management need professional oversight.
  4 fda 8 fda 9 fda

If Loyal wins approval, the next phase is less about convincing dog owners that aging matters, and more about becoming a standard part of senior dog care inside veterinary networks. The companies that dominate this category will be the ones that pair clinical proof with the strongest clinic relationships, refill infrastructure, and follow on products around diagnostics and age related care.